Conophylline Suppresses Angiotensin II-Induced Myocardial Fibrosis In Vitro via the BMP4/JNK Pathway

Area of Science:

• Cardiology
• Pharmacology
• Cell Biology

Background:

• Myocardial fibrosis is a key factor in heart disease progression.
• Understanding the molecular mechanisms underlying fibrosis is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the protective effects and mechanisms of conophylline on angiotensin II-induced myocardial fibrosis in vitro.
• To elucidate the specific signaling pathways involved in conophylline's action.

Main Methods:

• Primary cardiac fibroblasts were isolated from newborn rat hearts.
• Cells were treated with angiotensin II to induce fibrosis, followed by conophylline.
• Cell viability (MTT assay), collagen content (Sircol assay), and protein expression (Western blotting) were assessed.
• Specific pathway components including TGF-β, BMP4, Smad1/5/8, and JNK were analyzed.

Main Results:

• Conophylline significantly reduced angiotensin II-induced fibroblast viability and collagen production.
• It down-regulated α-smooth muscle actin (α-SMA) expression.
• Conophylline decreased elevated BMP4 levels and JNK activation without affecting the TGF-β pathway.
• The protective effect was mediated via the BMP4/JNK pathway, independent of JNK activation by anisomycin.

Conclusions:

• Conophylline demonstrates significant antifibrotic effects in a cardiac fibroblast model.
• The mechanism involves the inhibition of the BMP4/JNK signaling pathway.
• Conophylline represents a potential therapeutic agent for myocardial fibrosis.